North Carolina Biotech CEOs – A Roundtable Interview With “The Pink Sheet” DAILY, Part 1
This article was originally published in The Pink Sheet Daily
Executive Summary
CEOs from five North Carolina-based biotechs discuss the challenges present in today’s FDA approval process.
You may also be interested in...
North Carolina Biotech CEOs – A Roundtable Interview With “The Pink Sheet” DAILY (part 2 of 2)
“The Pink Sheet” DAILY recently talked with the CEOs of five North Carolina-based biotechs. In this portion of the roundtable, we discuss what smaller biotechs look for in collaborations with large pharmaceutical companies and how the smaller firms can position themselves to get the most benefit out of these deals.
North Carolina Biotech CEOs – A Roundtable Interview With “The Pink Sheet” DAILY (part 2 of 2)
“The Pink Sheet” DAILY recently talked with the CEOs of five North Carolina-based biotechs. In this portion of the roundtable, we discuss what smaller biotechs look for in collaborations with large pharmaceutical companies and how the smaller firms can position themselves to get the most benefit out of these deals.
GSK/Pozen Win Long-awaited Approval For Combo Migraine Drug
Treximet will hit the U.S. market in mid-May, GSK says.